Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)
Recombinant SARS-CoV-2 Vaccine (Sf9 Cell) Uses, Dosage, Side Effects, Food Interaction and all others data.
The Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a baculovirus expression system. In pre-clinical trial testing on mice, rabbits, and non-human primates, the candidate was able to induce a functional antibody response within 7-14 days of initial injection. It also provided protection in non-human primates to an in vivo challenge with SARS-CoV-2. These promising results have secured a Phase I trial (NCT04530656) to evaluate the safety, efficacy, and immunogenicity in healthy Chinese participants.
| Trade Name | Recombinant SARS-CoV-2 Vaccine (Sf9 Cell) |
| Generic | Recombinant SARS-CoV-2 Vaccine (Sf9 Cell) |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)
